SG11201804037XA - Injection solution comprising a non-nucleoside reverse-transcriptase inhibitor and poly(lactide-co-glycolide) - Google Patents

Injection solution comprising a non-nucleoside reverse-transcriptase inhibitor and poly(lactide-co-glycolide)

Info

Publication number
SG11201804037XA
SG11201804037XA SG11201804037XA SG11201804037XA SG11201804037XA SG 11201804037X A SG11201804037X A SG 11201804037XA SG 11201804037X A SG11201804037X A SG 11201804037XA SG 11201804037X A SG11201804037X A SG 11201804037XA SG 11201804037X A SG11201804037X A SG 11201804037XA
Authority
SG
Singapore
Prior art keywords
international
glycolide
lactide
poly
aromatic
Prior art date
Application number
SG11201804037XA
Inventor
Norbert Windhab
Rima Jaber
Axel Schröder
Kevin Burton
Tom Tice
Original Assignee
Evonik Roehm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Roehm Gmbh filed Critical Evonik Roehm Gmbh
Publication of SG11201804037XA publication Critical patent/SG11201804037XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property - Organization International Bureau res., 00) ..... ..s,„,„.1 (43) International Publication Date r 26 May 2017(26.05.2017) WIPO I PCT ID Hit (10) WO International 2017/084973 1111111111111111111111111111111111111111111111111111111111111t111111111111111 Publication Number Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/00 (2006.01) A61K 47/34 (2017.01) kind of national protection available): AE, AG, AL, AM, A61K 47/22 (2006.01) A61K 31/505 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP2016/077402 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 11 November 2016 (11.11.2016) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (25) Filing Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (26) Publication Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/255,866 16 November 2015 (16.11.2015) US (84) Designated States (unless otherwise indicated, for every 15197777.4 3 December 2015 (03.12.2015) EP kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: EVONIK ROHM GMBH [DE/DE]; TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, Kirschenallee, 64293 Darmstadt (DE). TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (72) Inventors: WINDHAB, Norbert; UbierstraBe 20, 65719 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Hofheim (DE). JABER, Rima; Rudolfstr. 4, 60327 Frank- SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, fort (DE). SCHRODER, Axel; Geschwister-Scholl-Str. 4, 64354 Reinheim (DE). BURTON, Kevin; 616 Founders GW, KM, ML, MR, NE, SN, TD, TG). Park Drive West, Hoover, Alabama 35226 (US). TICE, Published: Tom; 5317 Mountain Park Indian Circle, Springs, 21(3)) with international search report (Art Alabama 35124 (US). (74) Agent: GOTTSCHALK, Michael; Evonik Industries AG, CI-IPM-PAT, Postcode 84/339, Rodenbacher Chaussee 4, 63457 Hanau (DE). (54) Title: INJECTION SOLUTION COMPRISING A NON-NUCLEOSIDE REVERSE-TRANSCRIPTASE INHIBITOR AND POLY(LACTIDE-CO-GLYCOLIDE) Fig 1 2 1,8 1,6 1,4 E 1,2 11 13 r i i 1 .4t 0 u , -3 , 0 8 en 0,6 IN • R 752 - 5 0,4 Cr\ /a it 0,2 Ge 0 I - • R 752-15 O 0 1000 2000 3000 4000 5000 IN time [min] 11 C (57) : The invention is concerned with an injection solution, comprising an organic solvent, a copolymer, which is a ei poly(lactide-co-glycolide) dissolved in the organic solvent and a pharmaceutical active ingredient which is non-nucleoside inhibitor 0 of the HIV reverse transcriptase or of the HIV integrase, which contains aromatic and heterocyclic aromatic or aromatic and hetero - cyclic aromatic and aliphatic heterocyclic groups, wherein the content of the pharmaceutical active ingredient is from about 8 to about 25% by weight of the copolymer solution.
SG11201804037XA 2015-11-16 2016-11-11 Injection solution comprising a non-nucleoside reverse-transcriptase inhibitor and poly(lactide-co-glycolide) SG11201804037XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562255866P 2015-11-16 2015-11-16
EP15197777 2015-12-03
PCT/EP2016/077402 WO2017084973A1 (en) 2015-11-16 2016-11-11 Injection solution comprising a non-nucleoside reverse-transcriptase inhibitor and poly(lactide-co-glycolide)

Publications (1)

Publication Number Publication Date
SG11201804037XA true SG11201804037XA (en) 2018-06-28

Family

ID=54780205

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201804037XA SG11201804037XA (en) 2015-11-16 2016-11-11 Injection solution comprising a non-nucleoside reverse-transcriptase inhibitor and poly(lactide-co-glycolide)

Country Status (9)

Country Link
US (2) US10406098B2 (en)
EP (1) EP3377039B1 (en)
JP (1) JP6835841B2 (en)
KR (1) KR20180080322A (en)
CN (1) CN108289844B (en)
CA (1) CA3005313C (en)
IL (1) IL259303B2 (en)
SG (1) SG11201804037XA (en)
WO (1) WO2017084973A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021007525A (en) * 2018-12-21 2021-09-21 Univ Liverpool Nrti therapies.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US6537972B1 (en) 1997-06-02 2003-03-25 Subsidiary No. 3., Inc. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
CA2319495A1 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US8470359B2 (en) * 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
WO2003045351A1 (en) 2001-11-30 2003-06-05 Pfizer Inc. Controlled release polymeric compositions of bone growth promoting compounds
WO2006052373A2 (en) * 2004-11-08 2006-05-18 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and etravirine
JP2010540528A (en) * 2007-09-25 2010-12-24 トリメリス，インコーポレーテッド Novel synthesis of therapeutic antiviral peptides
BRPI0923161B1 (en) * 2008-12-24 2019-01-15 Janssen R&D Ireland one-piece implantable device containing rilpivirine
CA2852386C (en) * 2011-10-17 2019-05-21 Poly-Med, Inc. Absorbable in situ gel-forming system, method of making and use thereof
WO2015121413A1 (en) * 2014-02-14 2015-08-20 Aicuris Gmbh & Co. Kg New active pharmaceutical ingredient combinations with compounds based on tri(hetero)aryl pyrazoles
KR102019572B1 (en) * 2014-07-11 2019-09-06 길리애드 사이언시즈, 인코포레이티드 Modulators of toll-like receptors for the treatment of hiv
AU2015323321A1 (en) * 2014-09-26 2017-04-13 Glaxosmithkline Intellectual Property (No.2) Limited Long acting pharmaceutical compositions

Also Published As

Publication number Publication date
IL259303B (en) 2022-10-01
CN108289844B (en) 2021-09-14
US20190343762A1 (en) 2019-11-14
JP6835841B2 (en) 2021-02-24
CA3005313C (en) 2024-01-09
JP2018533614A (en) 2018-11-15
WO2017084973A1 (en) 2017-05-26
US20180318211A1 (en) 2018-11-08
CN108289844A (en) 2018-07-17
EP3377039B1 (en) 2024-01-03
CA3005313A1 (en) 2017-05-26
US10406098B2 (en) 2019-09-10
KR20180080322A (en) 2018-07-11
IL259303A (en) 2018-07-31
IL259303B2 (en) 2023-02-01
EP3377039A1 (en) 2018-09-26

Similar Documents

Publication Publication Date Title
SG11201803951QA (en) Oligonucleotides for inducing paternal ube3a expression
SG11201805120YA (en) Zika virus vaccine
SG11201804384UA (en) Geometric configurations for gastric residence systems
SG11201811470PA (en) Pyrazolopyrimidine derivatives as kinase inhibitor
SG11201907034PA (en) Methods of treating influenza
SG11201805940QA (en) Benzopyrazole compounds and analogues thereof
SG11201804312RA (en) Microbubble-chemotherapeutic agent complex for sonodynamic therapy
SG11201908560SA (en) Heterocyclic compounds useful as dual atx/ca inhibitors
SG11201804098TA (en) Purinones as ubiquitin-specific protease 1 inhibitors
SG11201906891RA (en) Methods for the administration of certain vmat2 inhibitors
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201804577RA (en) Fgf21 variants
SG11201900501RA (en) Cannabis composition
SG11201809277SA (en) Random copolymers of acrylates as polymeric friction modifiers, and lubricants containing same
SG11201407961WA (en) Risperidone or paliperidone implant formulation
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201408092UA (en) Endoprosthesis and delivery device for implanting such endoprosthesis
SG11201407368VA (en) Drug for preventing and/or treating polycystic kidney disease
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201907388YA (en) Carrier for carrying an ophthalmic lens during its treatment in a bath
SG11201810429UA (en) Anti-cd19 antibody formulations
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders